Drugs / Tulisokibart
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07405177 | Mar → Sep 2026 overdue | — | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06575595 | Sep 2024 → Jan 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06829225 | Jun → Nov 2024 | ulcerative colitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT05354349 | Apr → Aug 2022 | — | Prometheus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04676178 | Dec 2020 → Sep 2021 | — | Prometheus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 27 trials · 2 met primary | ||||||
| Phase 2 | NCT07486960 | Apr 2026 → Aug 2027 expected | psoriatic arthritis | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT07176390 | Oct 2025 → Sep 2026 overdue | rheumatoid arthritis | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07133633 | Sep 2025 → Jun 2027 expected | ankylosing spondylitis | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06956235 | Jun 2025 → Nov 2026 expected | hidradenitis suppurativa | Merck Sharp & Dohme LLC | Active not recruiting | Met primary |
| Phase 2 | NCT05270668 | Mar 2022 → Apr 2026 overdue | diffuse cutaneous systemic sclerosis, interstitial lung disease | Prometheus Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05013905 | Jul 2021 → Sep 2022 | Crohn disease | Prometheus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04996797 | Jul 2021 → Jun 2023 | ulcerative colitis | Prometheus Biosciences, Inc. | Completed | Met primary |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT06651281 | Nov 2024 → Dec 2037 expected | Crohn disease, ulcerative colitis | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06430801 | Jun 2024 → Oct 2028 expected | Crohn disease | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06052059 | Oct 2023 → Aug 2026 overdue | ulcerative colitis | Merck Sharp & Dohme LLC | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 4
All press releases naming this drug 7 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tulisokibart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07405177 ↗ |
| Known as | PRA023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04676178 ↗ |
| Action | Inhibit | “anti-TL1A monoclonal antibody tulisokibart” PMID 40456235 ↗ May 2025 |
| Modality | Monoclonal antibody | “BACKGROUND: Tulisokibart is a tumor necrosis factor-like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcerative colitis.” PMID 39321363 ↗ Sep 2024 |
| Route | Intravenous | “single intravenous doses of PRA023” NCT04676178 ↗ |